全文获取类型
收费全文 | 11846篇 |
免费 | 960篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 356篇 |
妇产科学 | 293篇 |
基础医学 | 1579篇 |
口腔科学 | 411篇 |
临床医学 | 1360篇 |
内科学 | 2264篇 |
皮肤病学 | 118篇 |
神经病学 | 967篇 |
特种医学 | 612篇 |
外国民族医学 | 1篇 |
外科学 | 1948篇 |
综合类 | 167篇 |
一般理论 | 7篇 |
预防医学 | 1076篇 |
眼科学 | 263篇 |
药学 | 527篇 |
1篇 | |
中国医学 | 13篇 |
肿瘤学 | 738篇 |
出版年
2021年 | 158篇 |
2020年 | 91篇 |
2019年 | 132篇 |
2018年 | 168篇 |
2017年 | 144篇 |
2016年 | 147篇 |
2015年 | 199篇 |
2014年 | 279篇 |
2013年 | 371篇 |
2012年 | 511篇 |
2011年 | 502篇 |
2010年 | 341篇 |
2009年 | 292篇 |
2008年 | 460篇 |
2007年 | 541篇 |
2006年 | 511篇 |
2005年 | 406篇 |
2004年 | 459篇 |
2003年 | 464篇 |
2002年 | 440篇 |
2001年 | 406篇 |
2000年 | 426篇 |
1999年 | 367篇 |
1998年 | 150篇 |
1997年 | 132篇 |
1996年 | 173篇 |
1995年 | 142篇 |
1994年 | 149篇 |
1993年 | 114篇 |
1992年 | 290篇 |
1991年 | 282篇 |
1990年 | 252篇 |
1989年 | 266篇 |
1988年 | 236篇 |
1987年 | 231篇 |
1986年 | 250篇 |
1985年 | 259篇 |
1984年 | 211篇 |
1983年 | 134篇 |
1982年 | 93篇 |
1981年 | 95篇 |
1979年 | 163篇 |
1978年 | 107篇 |
1977年 | 102篇 |
1976年 | 98篇 |
1975年 | 87篇 |
1974年 | 103篇 |
1972年 | 100篇 |
1971年 | 81篇 |
1970年 | 77篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
51.
Adel M. Mansour Robert W. Frenck Jr. Toni Darville Isabelle A. Nakhla Thomas F. Wierzba Yehia Sultan Magdy I. Bassiouny Kathryn McCarthy Richard F. Jacobs 《Clinical and Vaccine Immunology : CVI》2005,12(2):363-365
Cerebrospinal fluid gamma interferon (IFN-γ) and interleukin-10 levels in 39 patients with tuberculous meningitis were serially measured. Cytokine levels did not predict intracranial granuloma (IG) development, but IFN-γ levels in the top quartile after 1 month of therapy were highly associated (odds ratio = 18) with detection of an IG by computed tomography scanning. 相似文献
52.
Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. 总被引:2,自引:0,他引:2
Eric J Jacobs Carmen Rodriguez Elizabeth B Bain Yiting Wang Michael J Thun Eugenia E Calle 《Cancer epidemiology, biomarkers & prevention》2007,16(11):2213-2217
BACKGROUND: 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors, commonly known as statins, account for the great majority of cholesterol-lowering drug use in the United States. Long-duration statin use was associated with substantially reduced risk of advanced prostate cancer in a recent large prospective study. METHODS: We examined the association between use of cholesterol-lowering drugs and prostate cancer incidence by disease stage and grade among 55,454 men in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate RRs. RESULTS: During follow-up from 1997 to 2003, we identified 3,413 cases of incident prostate cancer, including 317 cases of advanced prostate cancer. After adjustment for age, history of prostate-specific antigen testing, and other potential prostate cancer risk factors, current use of cholesterol-lowering drugs for 5 or more years was not associated with overall prostate cancer incidence (multivariate adjusted rate ratio, 1.06; 95% confidence interval, 0.93-1.20), but was associated with a marginally statistically significant reduction in risk of advanced prostate cancer (rate ratio, 0.60; 95% confidence interval, 0.36-1.00). CONCLUSION: These results provide some support for the hypothesis that long-term statin use is associated with reduced risk of advanced prostate cancer. 相似文献
53.
P. E. Lønning M. Dowsett A. Jones D. Ekse S. Jacobs F. McNeil D. C. Johannessen T. J. Powles 《Breast cancer research and treatment》1992,23(1-2):57-62
Summary The clinical and biochemical effects of combined treatment with the two aromatase inhibitors aminoglutethimide and 4-hydroxyandrostenedione were evaluated in 10 patients suffering from advanced breast cancer. All patients had become resistant to treatment with one of the drugs before having combined treatment. Seven patients progressing on 4-hydroxyandrostenedione who had aminoglutethimide added to their treatment and achieved a further suppression of plasma oestradiol by a mean of 40.0% (p<0.05). Plasma oestrone was suppressed by a mean of 40.6% (p<0.025) and plasma oestrone sulphate was suppressed by a mean of 63.6% (p<0.025). Two of the patients, neither of whom had responded to 4-hydroxyandrostenedione alone, experienced objective tumour regression when aminoglutethimide was given in concert. Three patients progressing on aminoglutethimide who had 4-hydroxyandrostenedione added showed no further suppression of their plasma oestrogen levels, and no tumour regression was observed. These findings suggest a dose-response relationship between plasma oestrogen suppression at low postmenopausal levels and objective tumour response in breast cancer. 相似文献
54.
55.
There has been a traditional reluctance to remove a subluxed (ectopic) lens because of the high surgical risk. The use of closed intraocular microsurgical techniques, however, now allows greater intraoperative control with few complications. The authors present the results of subluxed lens extraction, by limbal or pars plana lensectomy, in 44 eyes of 24 patients, in which the indication for surgery was lens subluxation causing a reduction in visual acuity or uncorrectable refractive error. Visual acuity was improved in all cases after surgery, with no significant complications. Patients with reduced visual acuity secondary to ectopic lenses have a good visual prognosis after lensectomy using a closed intraocular microsurgical technique. 相似文献
56.
57.
Justin Lee Altshuler D. M.D David Jacobs M.B.A. D. M. D. † 《Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]》1992,4(1):12-15
There has been much interest in the in-office fabrication of ceramic posterior restorations using computer-aided design and computer-aided manufacture (CAD-CAM) units. One concern that practitioners have concerning the use of one of these systems is the initial expense of the CAD-CAM unit for the office. This article deals with the financial implications involved when considering the purchase or lease of a CEREC (CAD-CAM) unit. 相似文献
58.
F. A. MacNeill S. Jacobs M. Dowsett P. E. Lonning T. J. Powles 《Cancer chemotherapy and pharmacology》1995,36(3):249-254
This study investigated the influence of the aromatase inhibitor 4-hydroxyandrostenedione (4OHA, formestane), given orally, on peripheral aromatase activity and plasma oestradiol (E
2) levels in post-menopausal women with advanced breast cancer. The aim was to establish whether an optimal dose could be identified that had a pharmacological effectiveness comparable with that of parenteral 4OHA. A total of 13 post-menopausal women were studied before treatment and after a minimum of 4 weeks on treatment with one or more of the following doses: 125 mg once daily (od), 125 mg b.i.d. (bd) and 250 mg od. In all, seven aromatase studied were performed at 125 mg od; four, at 125 mg bd; and ten, at 250 mg od. Three patients were studied at all doses. E2 was measured concurrently and was available at all dose increments for seven patients. Given at doses of 125 mg od, 125 mg bd and 250 mg od, treatment with formestane inhibited in vivo aromatisation by 62.3%±9.5%, 70.0%±5.1% and 57.3%±5.3%, respectively (mean±SEM). Corresponding values for plasma E2 suppression were 30.7%±6.5%, 43.4%±4.5% and 42.9%±6.7%, respectively. Thus, apart from a somewhat better suppression of plasma E2 levels by the two higher doses as compared with 125 mg od, no significant difference in the degree of aromatase inhibition or plasma E2 suppression was observed. The suppression of E2 by oral 4OHA at 125 mg bd or 250 mg od approaches that achieved by the recommended parenteral schedule of 250 mg fortnightly, but inhibition of aromatase at this dose was substantially inferior. The findings are consistent with a hypothesis that 4OHA given orally may cause substantial plasma oestrogen suppression during part of the day, but neither the od nor the bd regimens investigated in the present study were capable of producing optimal aromatase inhibition. 相似文献
59.
60.
C L Daley P M Small G F Schecter G K Schoolnik R A McAdam W R Jacobs P C Hopewell 《The New England journal of medicine》1992,326(4):231-235
BACKGROUND. Tuberculosis typically develops from a reactivation of latent infection. Clinical tuberculosis may also arise from a primary infection, and this is thought to be more likely in persons infected with the human immunodeficiency virus (HIV). However, the relative importance of these two pathogenetic mechanisms in this population is unclear. METHODS. Between December 1990 and April 1991, tuberculosis was diagnosed in 12 residents of a housing facility for HIV-infected persons. In the preceding six months, two patients being treated for tuberculosis had been admitted to the facility. We investigated this outbreak using standard procedures plus analysis of the cultured organisms with restriction-fragment-length polymorphisms (RFLPs). RESULTS. Organisms isolated from all 11 of the culture-positive residents had similar RFLP patterns, whereas the isolates from the 2 patients treated for tuberculosis in the previous six months were different strains. This implicated the first of the 12 patients with tuberculosis as the source of this outbreak. Among the 30 residents exposed to possible infection, active tuberculosis developed in 11 (37 percent), and 4 others (13 percent) had newly positive tuberculin skin tests. Of 28 staff members with possible exposure, at least 6 had positive tuberculin-test reactions, but none had tuberculosis. CONCLUSIONS. Newly acquired tuberculous infection in HIV-infected patients can spread readily and progress rapidly to active disease. There should be heightened surveillance for tuberculosis in facilities where HIV-infected persons live, and investigation of contacts must be undertaken promptly and be focused more broadly than is usual. 相似文献